Search Medical Condition
Please enter condition
Please choose location from dropdown

Boisguillaume, France Clinical Trials

A listing of Boisguillaume, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (306) clinical trials

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor

Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years. At the physiopathology level, insulin secretion is determinant in the glucose tolerance abnormalities in CF. Indeed insulin secretion is dependent of the ...

Phase N/A

2.03 miles

Learn More »

API-CAT STUDY for APIxaban Cancer Associated Thrombosis

For patients completing at least 6 months of anticoagulant therapy in whom the cancer is active, the thrombotic risk is arguably ongoing and indefinite anticoagulation seems required. Given apixaban 5 mg bid is an alternative for the first 6 months of treatment, we intend to assess whether it is possible ...

Phase

2.05 miles

Learn More »

This is a multi-center Phase 1/2 open label trial of intratumoral G100 in patients with low grade NHL. Patients with NHL will be enrolled and receive G100 to an accessable tumor mass. Clinical response will be evaluated in the injected lesion and systemic (abscopal) responses will be evaluated in distal ...

Phase

2.05 miles

Learn More »

Post-ATU Study of Nivolumab

In order to reach goals of this study, collaboration had been established between BMS and the RIC-Mel network (network for Research and Clinical Investigational Research on Melanoma) (NCT03315468). The RIC-Mel network has set up a national database in order to reference the active file of melanoma patients in France. The ...

Phase N/A

2.05 miles

Learn More »

Impact of Emotional Skills of Young Women and Their Partner on Adjustment to Cancer

All women with breast cancer have to face, at any age, to numerous issues linked to cancer (incertitude, recurrence anxiety...) and to physical and psychosocial side effects of treatments which can degrade their life quality. However, young women (<45 years at diagnostic) have to face specific issues related to their ...

Phase N/A

2.05 miles

Learn More »

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned to continue with their regular medication. In addition, the study will assess safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Phase

2.05 miles

Learn More »

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

The trial will enroll 194 previously untreated DLBCL patients over 20 months, with the objective to send to the local investigator an extensive molecular tumor characterization by D38 in at least 80% of enrolled patients. The feasibility and efficiency will be demonstrated by deploying and operating a nation-wide network of ...

Phase N/A

2.05 miles

Learn More »

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned to continue with their regular medication. In addition, the study will assess safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Phase

2.05 miles

Learn More »

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Phase

2.1 miles

Learn More »

Very Preterm Children With Language Delay and Parent Intervention

EPILANG is an open randomized controlled study, in which the final assessment of the children (endpoint) will be conducted by professionals blinded to the treatment group. Some eligible children will first be screened using the parental questionnaire at 24 months corrected age (CA) of the EPIPAGE 2 cohort. Children with ...

Phase N/A

2.68 miles

Learn More »